Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt No Debt
APRI's Cash-to-Debt is ranked higher than
99% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. APRI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
APRI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.69 Max: No Debt
Current: No Debt
Equity-to-Asset -1.60
APRI's Equity-to-Asset is ranked lower than
100% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. APRI: -1.60 )
Ranked among companies with meaningful Equity-to-Asset only.
APRI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.6  Med: 0.42 Max: 0.87
Current: -1.6
-1.6
0.87
Piotroski F-Score: 5
Altman Z-Score: -81.73
Beneish M-Score: 6.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -203.29
APRI's Operating Margin % is ranked lower than
89% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. APRI: -203.29 )
Ranked among companies with meaningful Operating Margin % only.
APRI' s Operating Margin % Range Over the Past 10 Years
Min: -739.13  Med: -372.57 Max: -86.86
Current: -203.29
-739.13
-86.86
Net Margin % 61.22
APRI's Net Margin % is ranked higher than
99% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. APRI: 61.22 )
Ranked among companies with meaningful Net Margin % only.
APRI' s Net Margin % Range Over the Past 10 Years
Min: -1077.44  Med: -451.36 Max: 61.22
Current: 61.22
-1077.44
61.22
ROA % 44.85
APRI's ROA % is ranked higher than
98% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. APRI: 44.85 )
Ranked among companies with meaningful ROA % only.
APRI' s ROA % Range Over the Past 10 Years
Min: -217.31  Med: -116.71 Max: 44.85
Current: 44.85
-217.31
44.85
ROC (Joel Greenblatt) % -1283.05
APRI's ROC (Joel Greenblatt) % is ranked lower than
92% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. APRI: -1283.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
APRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2232.26  Med: -689.11 Max: -67.95
Current: -1283.05
-2232.26
-67.95
3-Year Revenue Growth Rate 6.60
APRI's 3-Year Revenue Growth Rate is ranked higher than
55% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. APRI: 6.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
APRI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.9 Max: 104.4
Current: 6.6
0
104.4
3-Year EBITDA Growth Rate -26.30
APRI's 3-Year EBITDA Growth Rate is ranked lower than
92% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. APRI: -26.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
APRI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.3  Med: -15.6 Max: 49.5
Current: -26.3
-41.3
49.5
3-Year EPS without NRI Growth Rate -37.20
APRI's 3-Year EPS without NRI Growth Rate is ranked lower than
92% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. APRI: -37.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
APRI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: -14.8 Max: 78.4
Current: -37.2
-44.4
78.4
GuruFocus has detected 5 Warning Signs with Apricus Biosciences Inc $APRI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» APRI's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:AOLS, OTCPK:PARNF, OTCPK:BKIT, OTCPK:AQSZF, NAS:EPIX, OTCPK:PVCT, OTCPK:PTLF, OTCPK:CBICF, OTCPK:KAYS, NAS:MYOS, OTCPK:TLFMF, OTCPK:SPLIF, OTCPK:CYIG, OTCPK:RLMD, AMEX:IGC, NAS:BNTC, OTCPK:CVSI, OTCPK:PUFXF, NAS:ARDM, OTCPK:ACUR » details
Traded in other countries:NXEM.Germany,
Headquarter Location:USA
Apricus Biosciences Inc is a pharmaceutical company. It focuses on the development of product candidates in the areas of urology and rheumatology. The company has two product candidates currently in development invluding Vitaros and RayVa.

Apricus Biosciences Inc.

Top Ranked Articles about Apricus Biosciences Inc

Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results

Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position
Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017 Conference Call / Webcast Today, Monday, March 13, 2017 at 4:30 p.m. ET SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (NASDAQ:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and full year of 2016 and provided a corporate update on its priorities for 2017. “Last week, we announced the divestiture of our ex-U.S. Vitaros interests to Ferring Pharmaceuticals. The closing of this transaction will allow us to focus our attention on the U.S. Vitaros NDA resubmission in the third quarter of this year, and advancing the RayVa clinical development program,” stated Richard W. Pascoe, Chief Executive Officer. “We continue to believe in the tremendous value that our pipeline potentially offers to patients, healthcare providers and shareholders as we look ahead and we are committed to working with Ferring to ensure a smooth transition of the Vitaros product outside of the United States. Importantly, this transaction creates a more streamlined, capital efficient organization with the potential to deliver on multiple regulatory, clinical and business development milestones over the next twelve months.” Strategic Priorities Apricus continues to focus on achieving the following key strategic objectives: Vitaros™(alprostadil)
Continue implementation of the U.S. regulatory approval strategy to address the safety issues raised by the FDA in the original Vitaros NDA submission.  Apricus anticipates a meeting with the FDA’s Office of Product Quality in the second quarter of 2017 to confirm the necessary device engineering and compliance requirements, following which the Company intends to resubmit the Vitaros NDA.  An FDA approval decision is expected after a six month review period;
Support the Ferring knowledge transfer, to ensure a smooth transition of certain ex-U.S. assets and rights related to Vitaros in an effort to ensure that Vitaros continues to grow as a global brand.
RayVa™(alprostadil)
Explore Orphan Drug Designation in the U.S. and EU;
Finalize clinical trial protocol and clinical trial material formulation work needed to initiate a Phase 2b study; and
Explore global or regional partnerships prior to initiating the Phase 2b study.
Corporate/Financial
Reduce operating expenses by approximately 30% in 2017 as compared to 2016 operating expenses;
Regain compliance with the minimum $2.5 million shareholder equity requirement as required for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(b)(2) on or before May 30, 2017.
Fourth Quarter and Full Year Financial Results Total revenues for the quarter and year to date periods ended December 31, 2016 were $0.4 million and $5.8 million, respectively, as compared to $2.6 million and $4.8 million for the quarter and year to date periods ended December 31, 2015, respectively. The decrease during the fourth quarter comparison was primarily due to license fee revenue of $2.25 million recognized in the fourth quarter of 2015 associated with the Company’s former partner, Ferring. The increase during the full year comparison was primarily due to increased license fee revenue and royalty revenue in the current year. Net loss for the quarter ended December 31, 2016 was $0.3 million, or loss per share of $0.04, compared to a net loss of $2.3 million, or $0.05 per share for the fourth quarter of 2015. Net loss for the year ended December 31, 2016 was $7.4 million, or loss per share of $1.14, compared to a net loss of $19.0 million, or loss per share of $3.83 for the year ended December 31, 2015. The reduction in the net loss during the current year periods as compared to the prior year periods is a result of decreased research and development expenses as well as decreased general and administrative expenses. Also reducing the net loss for the quarter and year ended December 31, 2016 was a non-cash change in the fair value of the Company’s warrant liabilities in the amount of $2.4 million and $7.5 million, respectively. As of March 8, 2017, the Company’s cash totaled $5.4 million, compared to $2.1 million as of December 31, 2016. Conference Call Details Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 85861485. The live and archived audio webcast can be accessed through the Investors Relations’ section of the Company’s website at www.apricusbio.com. Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (NASDAQ:APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights. For further information on Apricus, visit http://www.apricusbio.com. Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring B.V. in certain countries outside of the United States.  RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus’ ability to transition its ex-U.S. assets and rights related to Vitaros to Ferring; the timing and significance of the meeting with the FDA regarding device engineering and compliance; the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus’ plans for life-cycle development programs for Vitaros; Apricus’ development and partnering plans for RayVa; Apricus’ plans to reduce operating expenses and achieve profitability, including projected 2017 cost savings; and Apricus’ strategic objectives, including efforts to regain compliance with NASDAQ listing standards. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the risk that Apricus fails to provide the transition services as required by the transition services agreement with Ferring; the risk that the cost and other negative effects related to the reduction of Apricus’ workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from its workforce reduction and other cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus’ ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; Apricus’ ability to achieve U.S. and EU Orphan Designation for RayVa; the failure to meet NASDAQ continued listing requirements which could result in Apricus’ common stock being delisted from the exchange; Apricus’ ability to retain and attract key personnel; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to secure an ex-U.S. strategic partner for RayVa; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from Apricus. (Financial Information to Follow)
Selected Financial InformationConsolidated Statements of Operations(In thousands, except per share amounts)   Year Ended
 December 31,  2016 2015Revenue    License fee revenue $4,000  $3,600 Royalty revenue 1,088  650 Product sales 675  589 Total revenue 5,763  4,839      Cost of goods sold 511  922 Cost of Sandoz rights 3,380  â€” Gross profit 1,872  3,917      Research & development expense 6,831  14,649 General & administrative expense 8,434  10,516 Loss on disposal of assets 14  102 Total operating expense 15,279  25,267      Other income 5,974  2,327 Net loss $(7,433) $(19,023)     Basic and diluted loss per common share $(1.14) $(3.83)Weighted average common shares outstanding used for basic and diluted loss per share 6,516,662  4,972,858 
Consolidated Balance Sheets(In thousands)    December 31,
 2016 December 31,
 2015            Cash $2,087  $3,887 Other current assets 1,547  2,330 Property and equipment, net 1,006  1,290 Other long term assets 60  274  Total assets $4,700  $7,781       Current liabilities $4,644  $6,146 Notes payable 6,650  9,401 Warrant liabilities 846  1,841 Deferred revenue â€”  137 Other long term liabilities 76  200 Stockholders’ deficit (7,516) (9,944) Total liabilities and stockholders’ deficit $4,700  $7,781   

CONTACT:
Matthew Beck
[email protected]
The Trout Group
(646) 378-2933

Read more...
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (NASDAQ:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2016 financial results will be released on Monday, March 13, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Monday, March 13, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 85861485.  The live audio webcast can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for 30 days following the live call. About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (NASDAQ:APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development.  Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights. For further information on Apricus, visit http://www.apricusbio.com. Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States.  RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.  

CONTACT: Institutional / Retail Investors: Matthew Beck
[email protected]
The Trout Group LLC
(646) 378-2933


Read more...
Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
Apricus Expects to Receive Approximately $12.7 Million from Ferring Apricus to Focus on Vitaros U.S. NDA Re-Submission and Pipeline Assets Post-ClosingSAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (NASDAQ:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it completed the sale to Ferring International Center S.A. (“Ferring”) of Apricus’ ex-U.S. assets and rights related to Vitaros®, Apricus’ on-demand topical cream indicated for the treatment of patients with erectile dysfunction pursuant to a definitive agreement with Ferring.  Ferring is Apricus’ existing commercialization partner for Vitaros in Latin America and certain parts of Europe and Asia. Apricus will retain its Vitaros rights in the U.S. and it remains on track to re-submit the Vitaros NDA to the FDA in the third quarter of 2017.“This transaction reflects the continued execution of our corporate strategy of developing, obtaining regulatory approval for, and partnering novel topical prescription treatments in areas of significant unmet need,” said Richard Pascoe, Chief Executive Officer of Apricus. “Moreover, this transaction will allow us to focus our financial resources on obtaining U.S regulatory approval for Vitaros, accelerate the advancement of our clinical pipeline, strengthen our balance sheet with non-dilutive capital, extinguish our existing debt facility, eliminate certain future ex-U.S. Vitaros liabilities and lower our quarterly operating expenses by approximately 30%. I want to thank all of our commercial partners, including Ferring, for their commitment to making Vitaros a successful global brand.  We look forward to their continued success as we work towards a U.S. Vitaros NDA re-submission in the third quarter of this year.”Associated with the acquisition of the ex-U.S. assets and rights related to Vitaros, Ferring has agreed to pay Apricus an upfront payment of $11.5 million, due upon closing, and up to an additional $700,000 with respect to certain product inventory. Furthermore, the parties have entered into a transition services agreement, whereby Ferring has agreed to pay Apricus an amount equal to $500,000, payable over two calendar quarters, in exchange for Apricus’ assistance in facilitating the transfer of such assets and know-how to Ferring, subject to certain limitations. Ferring will be responsible for managing all Vitaros-related activities outside the U.S. at its cost and working with existing Vitaros commercialization partners outside the United States. About Ferring PharmaceuticalsHeadquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.For further information on Ferring or its products, visit www.ferring.com.About Apricus Biosciences, Inc.Apricus Biosciences, Inc. (NASDAQ:APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development.  Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.For further information on Apricus, visit http://www.apricusbio.com.Vitaros™ is Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of NexMed International Limited, and will be assigned to Ferring B.V. worldwide, excluding the United States.  RayVa™ is Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this report that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: statements regarding the cash proceeds from the sale of the purchased assets and under the transition services agreement, the extinguishment of outstanding debt and Apricus’ plans to  resubmit the Vitaros NDA. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus’ control, including, but not limited to: disruption of Apricus’ business and diversion of its management’s time and attention in order to provide transition services under the transition services agreement; Apricus not realizing the full economic benefit from the transaction, including as a result of indemnification claims under the asset purchase agreement and the retention by Apricus’ of certain liabilities associated with the product business; long-term financial risks associated with selling Apricus’ commercialized and registered products; risks related to Apricus’ planned resubmission of the Vitaros NDA; and other risks detailed in Apricus’ public periodic filings with the SEC. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from the Company.
CONTACT:

Matthew Beck
[email protected]
The Trout Group
(646) 378-2933

Read more...

Ratios

vs
industry
vs
history
PE Ratio 3.05
APRI's PE Ratio is ranked higher than
97% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.96 vs. APRI: 3.05 )
Ranked among companies with meaningful PE Ratio only.
APRI' s PE Ratio Range Over the Past 10 Years
Min: 2.47  Med: 3.03 Max: 6.97
Current: 3.05
2.47
6.97
Price-to-Owner-Earnings 3.40
APRI's Price-to-Owner-Earnings is ranked higher than
96% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. APRI: 3.40 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
APRI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.76  Med: 3.37 Max: 7.77
Current: 3.4
2.76
7.77
PB Ratio 10.64
APRI's PB Ratio is ranked lower than
92% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. APRI: 10.64 )
Ranked among companies with meaningful PB Ratio only.
APRI' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 9.65 Max: 102.82
Current: 10.64
1.42
102.82
PS Ratio 1.50
APRI's PS Ratio is ranked higher than
73% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. APRI: 1.50 )
Ranked among companies with meaningful PS Ratio only.
APRI' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 12.09 Max: 109.91
Current: 1.5
0.77
109.91
Current Ratio 1.99
APRI's Current Ratio is ranked lower than
58% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. APRI: 1.99 )
Ranked among companies with meaningful Current Ratio only.
APRI' s Current Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.99 Max: 85.68
Current: 1.99
0.12
85.68
Quick Ratio 1.99
APRI's Quick Ratio is ranked higher than
52% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. APRI: 1.99 )
Ranked among companies with meaningful Quick Ratio only.
APRI' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 1.99 Max: 85.68
Current: 1.99
0.12
85.68
Days Inventory 64.18
APRI's Days Inventory is ranked higher than
78% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. APRI: 64.18 )
Ranked among companies with meaningful Days Inventory only.
APRI' s Days Inventory Range Over the Past 10 Years
Min: 23.31  Med: 89.65 Max: 147.27
Current: 64.18
23.31
147.27
Days Sales Outstanding 24.73
APRI's Days Sales Outstanding is ranked higher than
88% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. APRI: 24.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
APRI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.13  Med: 28.34 Max: 87.02
Current: 24.73
2.13
87.02
Days Payable 72.44
APRI's Days Payable is ranked higher than
51% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. APRI: 72.44 )
Ranked among companies with meaningful Days Payable only.
APRI' s Days Payable Range Over the Past 10 Years
Min: 72.44  Med: 201.34 Max: 625.49
Current: 72.44
72.44
625.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.30
APRI's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. APRI: -27.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
APRI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.3  Med: -26.6 Max: -9
Current: -27.3
-62.3
-9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 14.50
APRI's Price-to-Net-Current-Asset-Value is ranked lower than
75% of the 521 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.35 vs. APRI: 14.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
APRI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.63  Med: 12.55 Max: 1870
Current: 14.5
2.63
1870
Price-to-Tangible-Book 10.64
APRI's Price-to-Tangible-Book is ranked lower than
85% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. APRI: 10.64 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
APRI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.1  Med: 9.06 Max: 77.62
Current: 10.64
2.1
77.62
Price-to-Median-PS-Value 0.13
APRI's Price-to-Median-PS-Value is ranked higher than
98% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. APRI: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APRI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 1.48 Max: 722.73
Current: 0.13
0.12
722.73
Earnings Yield (Greenblatt) % -107.53
APRI's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. APRI: -107.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APRI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -338.9  Med: -28.45 Max: -5
Current: -107.53
-338.9
-5

More Statistics

Revenue (TTM) (Mil) $5.14
EPS (TTM) $ 0.38
Beta-0.53
Short Percentage of Float22.48%
52-Week Range $0.86 - 5.95
Shares Outstanding (Mil)12.77

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.89 1.49
EPS without NRI ($) -0.89 1.49
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for APRI

Headlines

Articles On GuruFocus.com
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results May 11 2017 
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study May 04 2017 
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference C May 04 2017 
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements May 02 2017 
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering Apr 21 2017 
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Mar 13 2017 
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Mar 09 2017 
Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Mar 08 2017 
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Edited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT May 19 2017
Apricus posts 1Q profit May 11 2017
Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results May 11 2017
Investor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call May 11 2017
Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study May 04 2017
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference... May 04 2017
Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements May 02 2017
Apricus Biosciences Announces Pricing of $7.0 Million Public Offering Apr 21 2017
ETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017 Apr 19 2017
Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Apr 13 2017
Apricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Apricus reports 4Q loss Mar 13 2017
Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Mar 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}